$9m From ‘Transformational Acquisitions’ Keeps Advanz Growing In Second Quarter
Plans To Make Its Troubled Acquisitions Profitable
Advanz added $5.5m of revenue from its recently acquired alprostadil products and $3.3m from Correvio in the second quarter of 2020. After seeking approval for seven medicines during the second quarter alone, the company plans to launch another 17 products in 2020.
